KBI Biopharma, Inc., a JSR Life Sciences company and CDMO, and Argonaut Manufacturing Services, Inc., a CMO for biopharmaceutical and diagnostics, entered into a strategic alliance to offer end-to-end drug substance and drug product manufacturing services. The arrangement integrates drug substance and drug product manufacturing by combining KBI’s drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish.

“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics,” said J.D. Mowery, President, and CEO of KBI Biopharma. “Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development.”

Wayne Woodard, founder, and CEO of Argonaut said, “We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations. Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products.”